OrthoPediatrics Corp.

DB:2X7 Stock Report

Market Cap: €521.9m

OrthoPediatrics Valuation

Is 2X7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2X7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2X7's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2X7's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2X7?

Key metric: As 2X7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2X7. This is calculated by dividing 2X7's market cap by their current revenue.
What is 2X7's PS Ratio?
PS Ratio2.9x
SalesUS$189.67m
Market CapUS$549.46m

Price to Sales Ratio vs Peers

How does 2X7's PS Ratio compare to its peers?

The above table shows the PS ratio for 2X7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.2x
PHH2 Paul Hartmann
0.3xn/a€710.3m
EUZ Eckert & Ziegler
2.9x6.0%€802.1m
DRW3 Drägerwerk KGaA
0.2x4.2%€792.8m
SBS Stratec
1.4x7.7%€353.7m
2X7 OrthoPediatrics
2.9x16.8%€549.5m

Price-To-Sales vs Peers: 2X7 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does 2X7's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$834.66m
PHH2 Paul Hartmann
0.3xn/aUS$747.81m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
2X7 2.9xIndustry Avg. 3.4xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2X7 is good value based on its Price-To-Sales Ratio (2.9x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 2X7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2X7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.9x
Fair PS Ratio3.8x

Price-To-Sales vs Fair Ratio: 2X7 is good value based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2X7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€21.00
€38.51
+83.4%
16.2%€47.35€26.52n/a6
Nov ’25€24.40
€37.91
+55.4%
16.2%€45.86€25.68n/a6
Oct ’25€24.20
€38.25
+58.1%
11.4%€45.18€30.72n/a6
Sep ’25€28.00
€37.80
+35.0%
14.5%€45.36€27.22n/a6
Aug ’25€28.40
€38.99
+37.3%
10.7%€45.87€32.11n/a6
Jul ’25€26.60
€39.98
+50.3%
8.8%€46.49€35.33n/a6
Jun ’25€30.40
€39.98
+31.5%
8.8%€46.49€35.33n/a6
May ’25€27.20
€37.64
+38.4%
13.9%€47.06€32.00n/a6
Apr ’25€26.80
€36.12
+34.8%
15.5%€45.72€29.26n/a6
Mar ’25€25.20
€35.83
+42.2%
16.8%€46.13€28.60n/a6
Feb ’25€24.00
€35.83
+49.3%
16.8%€46.13€28.60n/a6
Jan ’25€30.00
€36.51
+21.7%
13.7%€45.45€29.08n/a6
Dec ’24€28.20
€38.49
+36.5%
22.1%€56.10€29.92n/a6
Nov ’24€23.00
€47.55
+106.7%
18.4%€57.06€29.48€24.406
Oct ’24€30.60
€49.62
+62.2%
7.7%€54.63€43.70€24.206
Sep ’24€35.20
€49.62
+41.0%
7.7%€54.63€43.70€28.006
Aug ’24€37.80
€49.62
+31.3%
7.7%€54.63€43.70€28.406
Jul ’24€39.80
€51.48
+29.4%
6.1%€56.33€47.24€26.606
Jun ’24€40.40
€51.48
+27.4%
6.1%€56.33€47.24€30.406
May ’24€45.80
€51.23
+11.9%
7.2%€56.72€46.66€27.206
Apr ’24€40.00
€51.90
+29.7%
7.5%€58.15€47.83€26.806
Mar ’24€41.20
€51.90
+26.0%
7.5%€58.15€47.83€25.206
Feb ’24€43.20
€50.59
+17.1%
8.6%€57.03€46.00€24.006
Jan ’24€35.60
€54.76
+53.8%
10.0%€63.07€47.81€30.006
Dec ’23€42.00
€54.76
+30.4%
10.0%€63.07€47.81€28.206
Nov ’23€42.40
€56.19
+32.5%
14.3%€70.87€47.58€23.006

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sensus Healthcare

US$112.8m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$6.45

7D

4.0%

1Y

251.1%

Ship Healthcare Holdings

JP¥194.6b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.30

7D

-9.6%

1Y

-4.7%

CVS Health

US$68.3b

Provides health solutions in the United States.

CVS

US$52.20

7D

-2.4%

1Y

-16.6%